ENJUVIA (estrogens, conjugated synthetic b) by Aspen Surgical is clinical pharmacology endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Approved for the: treatment of moderate to severe vasomotor symptoms associated with menopause. First approved in 2004.
Drug data last refreshed 19h ago · AI intelligence enriched 1mo ago
ENJUVIA is an oral tablet containing conjugated synthetic estrogens (synthetic estrogen B) approved for treatment of moderate to severe vasomotor symptoms associated with menopause. The drug works by binding to nuclear estrogen receptors in estrogen-responsive tissues, restoring hormone levels that decline after menopause and reducing elevated gonadotropin levels. ENJUVIA provides slow, sustained release of estrogens over several hours for steady-state hormone replacement.
Product nearing loss of exclusivity with low commercial activity (1 linked job) signals minimal team expansion and focus on brand defense rather than growth initiatives.
CLINICAL PHARMACOLOGY Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal…
Worked on ENJUVIA at Aspen Surgical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy
Career opportunities on ENJUVIA are highly limited, with only 1 linked job and focus restricted to general commercial roles. This mature product nearing LOE is unsuitable for career growth, with most activity concentrated on brand maintenance and revenue protection rather than innovation or market expansion.
1 open roles linked to this drug